(Alliance News) - Mercia Asset Management PLC on Wednesday said that it has invested GBP1 million in cell and gene therapy development company Oxgene.
The asset manager made the investment as part of a GBP3 million funding round by Oxgene.
Oxgene combines engineering, biology, robotics and bioinformatics to accelerate the design, discovery and manufacture of new biologics.
Working across the fields of gene therapy, gene editing and antibody therapeutics, Oxgene has delivered over 1,000 engineered cell lines and is working with the Native Antigen Co, a Mercia investee, to accelerate the production of Covid-19 antigens.
Shares in Mercia Asset Management closed 7.2% higher at 21.98 pence each in London on Wednesday.
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Mercia Asset (MERC)